



January 9, 2014
For Immediate Release
Contact: Joanne Gere
Executive Director
jgere@biopharmaresearchcouncil.org
609-203-6852

PRESS RELEASE

**Dimitris Agrafiotis, Ph.D. to Speak at
D2D: From Data to Drugs & Diagnostics**

Cloud Computing, Big Data Analytics, Personalized Medicine, and More
June 11-12, 2014 in New Jersey

(Tinton Falls, NJ) The BioPharma Research Council (BRC) will present D2D: From Data to Drugs & Diagnostics, June 11-12, 2014 at the New Jersey Convention and Exposition Center in Edison, NJ.

D2D will bring together researchers, developers and suppliers from across the pharmaceutical/biotechnology enterprise, including industry, academia, government agencies, suppliers, and nonprofit organizations in the life sciences space.

They will discuss emerging innovations in the generation, collection, security and analysis of biopharmaceutical research data. This two-day IT Congress will focus on Cloud Computing, Big Data Analytics, Personalized Medicine, and more.

“D2D’s highly interactive format, including keynotes, presentations, panels, posters, and interactions with exhibitors, will stimulate fresh perspectives and potentially lead to collaborations among attending thought leaders,” says Dolly Koltchev, Ph.D, BRC Program Director.

Dimitris Agrafiotis, Ph.D., Vice President of Informatics and Enterprise Architecture at Covance, will address “Accurate Prediction of Clinical Stroke Scales from Robotic Measurements”. His discussion will investigate the efficacy and objectivity of robotic devices in recording the kinematics of human movements.

Additional confirmed speakers include Michael Cantor, (Pfizer); Gabor Fari, (Microsoft); Deborah Dougherty (Rutgers Business School); Jennifer Goldsmith (Veeva Systems), and James Pierce, (Appian).

Since 2009, the BioPharma Research Council has been developing a vibrant community for

researchers as they navigate today's complex environments. Its unique resources - including deep relationships with leading companies and suppliers - and its agile approaches, have established continual opportunities for breakthrough discussion and debate throughout the drug discovery and delivery pipeline. These lively assemblies reflect the organization's mission to play a positive role in creating more efficient and effective treatments and medicines for the advancement of human health.

For more detailed updated information and registration: www.brcd2d.com

---###---

Note to the Editor: Multiple advance webinars will lead up to this event.
Speakers may be made available for comment.